Nautilus Biotechnology, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This annual filing reports full-year results, not standalone fourth-quarter results. Nautilus is a development-stage life sciences company developing a proteomics platform; it had not commercialized products or generated revenue by year-end.
Business context and operating progress
The company is developing an integrated instrument, consumables and software system for single-protein analysis. Its commercialization plan has three phases: research collaborations, an early-access program, and broader commercial launch. Collaborators disclosed include Genentech, Amgen, MD Anderson and, in January 2023, the Translational Genomics Research Institute. The company said these research collaborations would not generate revenue.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $37.7 million | $29.4 million |
| General and administrative expense | $25.9 million | $21.1 million |
| Total operating expenses | $63.6 million | $50.5 million |
| Interest income | $5.8 million | $0.3 million |
| Net loss | $57.9 million | $50.3 million |
| Net loss per share, basic and diluted | $0.46 | $0.60 |
| Net cash used in operating activities | $45.8 million | $39.2 million |
Operating expenses increased 26%; R&D rose 28% and G&A rose 23%, primarily from higher personnel, facilities and development costs. Net loss increased 15%, partly offset by higher interest income as rates rose. No revenue means product margins are not yet meaningful.
At December 31, 2022, cash and cash equivalents were $114.5 million and short-term investments were $69.9 million, totaling $184.5 million in cash and short-term investments. Including $129.2 million of long-term investments, cash and investments totaled $313.6 million. Management said available cash, cash equivalents and short-term investments were expected to fund planned operations for at least 12 months from the filing/financial-statement issuance date; this is not a guarantee of runway if spending or development plans change.
Total liabilities were $35.1 million, primarily operating lease liabilities; the filing reports no conventional borrowings. Operating lease liabilities totaled $30.3 million. Total assets were $350.1 million, stockholders’ equity was $314.9 million, and accumulated deficit was $138.6 million. Investing cash outflow was $25.7 million, mainly reflecting net purchases of securities and $2.3 million of property and equipment. Financing provided $0.6 million, primarily from stock-option exercises and employee stock purchases.
Outlook, risks and other notable items
- Management targeted meaningful early-access engagements and associated revenue beginning in early 2024, followed by broad commercialization in mid-2024. These are forward-looking targets, dependent on development, validation and manufacturing execution.
- The platform remains under development and requires scientific and technical validation. The company cautioned that it may face delays, performance shortfalls, limited market adoption, competition and the need for additional capital.
- Manufacturing readiness and supply are material risks: the company relies on third parties, including single-source suppliers for some components and materials, and has no commercial-scale manufacturing experience.
- Products were intended to be sold for research use only. Clinical or diagnostic use could trigger FDA and other regulatory requirements; rules affecting research-use products and laboratory-developed tests remain uncertain.
- Investments had $1.9 million of gross unrealized losses at year-end, recorded in other comprehensive loss. Management stated that a hypothetical 100-basis-point interest-rate change would change investment fair value by $2.4 million; such a change would be realized only if securities were sold before maturity.
- Open purchase commitments were $1.7 million, expected to be received within 12 months. The company reported no pending legal proceedings expected to have a material adverse effect.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded internal control over financial reporting was effective; the auditor did not attest to internal controls because of the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Whether platform performance, reproducibility and customer validation support the company’s stated early-access and mid-2024 commercialization targets.
- Actual cash burn, investment liquidity and runway relative to the stated 12-month funding expectation, including the distinction between $184.5 million of cash and short-term investments and $313.6 million of total cash and investments.
- Progress in qualifying suppliers, scaling production and controlling the costs and quality of instruments, flow cells and reagents.
- Whether collaborations lead to independent, peer-reviewed evidence and future customer demand; the disclosed research agreements themselves are not revenue-generating.
- Potential dilution or financing needs, and the regulatory implications if products or customer uses extend beyond research-only applications.